Literature DB >> 18585886

Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study.

Mohammed Al-Omran1, Muhammad M Mamdani, Thomas F Lindsay, Magda Melo, David N Juurlink, Subodh Verma.   

Abstract

BACKGROUND: Current evidence suggests that statin use plays an important role in improving adverse cardiovascular outcomes in patients with atherosclerosis. However, limited population-based data are available on use of statin therapy in these patients in Canada. We sought to study trends in statin use to treat these patients in Ontario during a 10-year period.
METHODS: We conducted a population-based cross-sectional time series analysis between April 1, 1995, and March 31, 2004, using health care data from Ontario, Canada.
RESULTS: During the study period, 343,154 elderly patients with atherosclerosis were identified. Of these, 235,615 (68.7%) had coronary artery diseases (CAD), 115,012 (33.5%) had cerebrovascular disease (CVD), and 23,886 (7.0%) had peripheral arterial disease (PAD). About 46% were women, and mean patient age was 77.1 (SD, 7.5) years. During the study period, the percentage of patients treated with a statin in each group increased considerably, from 9.8% to 55.3% in all atherosclerotic patients (P < .01), from 11.8% to 61.2% in CAD patients (P < .01), from 5.3% to 41.2% in CVD patients (P < .01), and from 6.8% to 43.3% in PAD patients (P < .01). During the entire study period, the percentage of statin users was lowest among PAD and CVD patients, followed by patients with both a history of PAD and CVD.
CONCLUSION: The use of statin therapy in elderly patients with symptomatic atherosclerosis has increased substantially during the past decade, but many patients remain untreated. The suboptimal use is greatest among patients with PAD or CVD, or both, and lowest in patients with CAD. Given the heightened risk of cardiovascular adverse outcomes in patients with atherosclerosis, these data have important and immediate implications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585886     DOI: 10.1016/j.jvs.2008.04.057

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  6 in total

Review 1.  Medication adherence in patients with diabetes and dyslipidemia: associated factors and strategies for improvement.

Authors:  Lucas N Marzec; Thomas M Maddox
Journal:  Curr Cardiol Rep       Date:  2013-11       Impact factor: 2.931

2.  Improving long-term adherence to statin therapy: a qualitative study of GPs' experiences in primary care.

Authors:  Karen Krüger; Niklas Leppkes; Sabine Gehrke-Beck; Wolfram Herrmann; Engi A Algharably; Reinhold Kreutz; Christoph Heintze; Iris Filler
Journal:  Br J Gen Pract       Date:  2018-04-23       Impact factor: 5.386

3.  Improving clinician self-efficacy does not increase asthma guideline use by primary care clinicians.

Authors:  Michelle M Cloutier; Howard Tennen; Dorothy B Wakefield; Kevin Brazil; Charles B Hall
Journal:  Acad Pediatr       Date:  2012-05-26       Impact factor: 3.107

4.  Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease.

Authors:  Yevgeniy Khariton; Krishna K Patel; Paul S Chan; Yashashwi Pokharel; Jingyan Wang; John A Spertus; David M Safley; William R Hiatt; Kim G Smolderen
Journal:  Clin Cardiol       Date:  2018-10-19       Impact factor: 2.882

Review 5.  Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery.

Authors:  Robert D Sanders; Amanda Nicholson; Sharon R Lewis; Andrew F Smith; Phil Alderson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-03

6.  Population-based cross-sectional study of 11 645 Spanish nonagenarians with type 2 diabetes mellitus: cardiovascular profile, cardiovascular preventive therapies, achievement goals and sex differences.

Authors:  Miguel Angel Salinero-Fort; Jose M Mostaza-Prieto; Carlos Lahoz-Rallo; José Ignacio Vicente Díez; Juan Cárdenas-Valladolid
Journal:  BMJ Open       Date:  2019-09-20       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.